These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 15979320)

  • 1. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
    Taylor AL; Marcus R; Bradley JA
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):155-67. PubMed ID: 15979320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH; Russ GR; Coates PT
    Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM; Crawford DH
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J; Einsele H; Gil L; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
    J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation.
    Bakker NA; van Imhoff GW; Verschuuren EA; van Son WJ
    Transpl Int; 2007 Mar; 20(3):207-18. PubMed ID: 17291214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttransplant lymphoproliferative disorder.
    Everly MJ; Bloom RD; Tsai DE; Trofe J
    Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient.
    Dharnidharka VR; Douglas VK; Hunger SP; Fennell RS
    Pediatr Transplant; 2004 Feb; 8(1):87-90. PubMed ID: 15009846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplant lymphoproliferative disorder: a review.
    Loren AW; Porter DL; Stadtmauer EA; Tsai DE
    Bone Marrow Transplant; 2003 Feb; 31(3):145-55. PubMed ID: 12621474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
    Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG;
    Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Latest update on immunotherapy of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease].
    Hao QF; Sheng GY; Luan Z
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Sep; 15(9):795-9. PubMed ID: 24034931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment for Epstein-Barr virus-associated PTLD.
    Gross TG
    Herpes; 2009 Jan; 15(3):64-7. PubMed ID: 19306606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis.
    Capello D; Rossi D; Gaidano G
    Hematol Oncol; 2005 Jun; 23(2):61-7. PubMed ID: 16216037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant lymphoproliferative disorders.
    Singavi AK; Harrington AM; Fenske TS
    Cancer Treat Res; 2015; 165():305-27. PubMed ID: 25655616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients.
    Preiksaitis JK
    Clin Infect Dis; 2004 Oct; 39(7):1016-23. PubMed ID: 15472855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transplantation-related lymphoproliferative disorder: a model for human immunodeficiency virus-related lymphomas.
    Swinnen LJ
    Semin Oncol; 2000 Aug; 27(4):402-8. PubMed ID: 10950366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
    Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW
    Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
    Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.